RxDoctor Payments Data

Sharon Koehler, APRN

Nurse Practitioner · Omaha, NENPI 1366162232

Payments from drug & device makers

$1,254in general payments, 2019–2025

Across 43 payments — averaging $29.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$233
  • SK Life Science, Inc.$166
  • Acadia Pharmaceuticals Inc$163
  • AbbVie$138
  • Neurelis, Inc.$86
  • TG Therapeutics, Inc.$75
  • plus $392 from 11 others

What the payments were for

  • Food & beverage$1,254100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,254 in reported general payments places this provider in the 75th percentile of 924 nurse practitioner providers in Nebraska.

See all nurse practitioner providers in Nebraska

Medicare billing

Part B allowed, 2024
$23,322
Medicare patients
138
Services billed
282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)12$51,883
BriviactBrivaracetam19$49,099
LamictalLamotrigine13$18,087
XcopriCenobamate13$15,469
Levetiracetam334$15,223
Lacosamide63$14,238
Emgality PenGalcanezumab-Gnlm15$10,245
Tegretol XrCarbamazepine14$5,047
Lamotrigine ErLamotrigine37$4,800
Carbamazepine ErCarbamazepine26$3,280
Oxcarbazepine26$3,158
Divalproex Sodium ErDivalproex Sodium21$2,579
Pregabalin27$2,526
Carbamazepine50$2,371
Levetiracetam ErLevetiracetam20$2,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$166$15,46913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 924 nurse practitioner providers in Nebraska.

Other nurse practitioner in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →